Intellia appoints Bill Chase to board; Caroline Dorsa to retire June 15, 2023

Intellia Therapeutics, Inc.

Bill Chase, former AbbVie CFO, appointed as Class III director, effective April 14, 2023.
Caroline Dorsa to retire from board on June 15, 2023, after being appointed chair of Biogen's board.
Chase will serve on audit committee and succeed Dorsa as audit committee chair.
Chase received grant of 14,931 stock options and 10,483 RSUs under director compensation program.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bill Chase

Class III Director

NTLA · Intellia Therapeutics, Inc.

Effective: 2023-04-14
Filed: April 17, 2023, 7:59 PM ET

the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bill Chase was appointed as Class III Director at Intellia Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-103787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.